Guru Fundamental Report for JNJ

Validea's guru fundamental report assigns Johnson & Johnson (JNJ) a 77% rating using its P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained growth potential. As a large-cap growth stock in the Biotechnology & Drugs sector, JNJ's score is just below the 80% threshold typically indicating investment interest, despite passing most of the model's fundamental criteria, including Return on Assets and Cash Flow from Operations, though it failed on Advertising to Assets and Research & Development to Assets.

Analysis

Johnson & Johnson (JNJ) scores a 77% rating under Validea's P/B Growth Investor model, which is based on the strategy of Partha Mohanram for identifying low book-to-market stocks with indicators of sustained growth. This score places JNJ just below the 80% threshold that typically signifies investment interest from this model. As a large-cap stock in the Biotechnology & Drugs industry, JNJ demonstrates strong underlying fundamentals by passing seven key tests, including those for its book-to-market ratio, return on assets (ROA), cash flow from operations, and stability in both ROA and sales. However, the analysis reveals two notable weaknesses according to this specific framework: JNJ fails the model's criteria for both Advertising to Assets and Research and Development to Assets. The failure on the R&D metric is particularly significant for a company in its sector, as it may suggest that investment in its future product pipeline does not meet the model's aggressive growth standards.

Key Decisions for Investors

• Given that JNJ's 77% score is solid but falls just short of the 80% interest threshold, investors might consider this a 'hold' signal, reflecting strong core fundamentals but a lack of decisive growth characteristics according to this specific model.
• Investors should closely monitor Johnson & Johnson's R&D expenditure, as its failure on this metric could be a leading indicator of slowing long-term innovation and growth, a critical risk factor in the biotechnology industry.
• Since this analysis is based on a single growth-focused model, investors with a value or dividend-income strategy may interpret the positive signals on cash flow and return on assets more favorably, weighing them against the model's specific growth-related concerns.